*Wang SE, Xiang B, Zent R, Quaranta V, Pozzi A, *Arteaga CL. Cancer Res. 2009 Jan;69(2):475-82. TGF-ß induces clustering of HER2 and integrins by activating Src-FAK and receptor association to the cytoskeleton. (*Corresponding author.)
*Wang SE, Xiang B, Criswell TL, DeBusk LM, Lin PC, Zent R, Johnson DH, *Arteaga CL. 2009. Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators. Manuscript in preparation. (*Corresponding author.)
Xiang B, Wang SE, Reynolds AB, Arteaga CL. 2009. Cell-cell adhesion modulates action of ErbB receptor tyrosine kinase inhibitors through the MAGI-2/PTEN signalosome. Manuscript submitted.
Wang SE, Hinow P, Bryce N, Weaver AM, Estrada L, Arteaga CL, Webb GF. Comput Math Meth Med. 2009. A mathematical model quantifies proliferation and motility effects of TGF-ß on cancer cells. In press.
Hinow P, Gerlee P, McCawley LJ, Quaranta V, Ciobanu M, Wang S, Graham JM, Ayati BP, Claridge J, Swanson KR, Loveless M, Anderson ARA. Math Biosci Eng. 2009. A spatial model of tumor-host interaction: application of chemotherapy. In press.
*Wang SE, Xiang B, Guix M, Olivares MG, Parker J, Chung CH, Pandiella A, *Arteaga CL. Mol Cell Biol. 2008 Sep;28(18):5605-20. TGF-ß engages TACE and ErbB3 to activate PI3K/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. (*Corresponding author.)
Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S, Rinehart C, Seidel B, Yee D, Arteaga CL, Engelman JA. J Clin Invest. 2008 Jul;118(7):2609-19. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.
Wang SE, Narasanna A, Whitwell CW, Wu FY, Friedman DB, Arteaga CL. J Biol Chem. 2007 Feb;282(8):5661-9. Convergence of p53 and TGF-ß signaling on activating expression of the tumor suppressor gene maspin in mammary epithelial cells.
Hinow P, *Wang SE, Arteaga CL, Webb GF. Theor Biol Med Model. 2007 Apr;4(1):14. A mathematical model separates quantitatively the cytostatic and cytotoxic effects of a HER2 tyrosine kinase inhibitor. (*The first two authors contributed equally.)
Friedman DB, Wang SE, Whitwell CW, Caprioli RM, Arteaga CL. Mol Cell Proteomics. 2007 Jan;6(1):150-69. Multi-variable difference gel electrophoresis and mass spectrometry: a case study on TGF-ß and ErbB2 signaling.
Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S, Carpenter G, Gazdar AF, Muthuswamy SK, Arteaga CL. Cancer Cell. 2006 Jul;10(1):25-38. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.
Wang SE, Shin I, Wu FY, Friedman DB, Arteaga CL. Cancer Res. 2006 Oct;66(19):9591-600. HER2/Neu (ErbB2) signaling to Rac1-Pak1 is temporally and spatially modulated by TGF-ß.
Wu FY, *Wang SE, Sanders ME, Shin I, Rojo F, Baselga J, Arteaga CL. Cancer Res. 2006 Feb;66(4):2162-72. Reduction of cytosolic p27Kip1 inhibits cancer cell motility, survival, and tumorigenicity. (*The first two authors contributed equally.)
Qu S, Rinehart C, Wu HH, Wang SE, Carter B, Xin H, Kotlikoff M, Arteaga CL. Genesis. 2006 Sep;44(10):477-86. Gene targeting of ErbB3 using a Cre-mediated unidirectional DNA inversion strategy.
Biswas S, Criswell TL, Wang SE, Arteaga CL. Clin Cancer Res. 2006 Jul;12(14 Pt 1):4142-6. Inhibition of transforming growth factor-ß signaling in human cancer: targeting a tumor suppressor network as a therapeutic strategy.
Wang SE, Wu FY, Shin I, Qu S, Arteaga CL. Mol Cell Biol. 2005 Jun;25(11):4703-15. Transforming growth factor ß (TGF-ß)-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-ß function.
Yu Y, Wang SE, Hayward GS. Immunity. 2005 Jan;22(1):59-70. The KSHV immediate-early transcription factor RTA encodes ubiquitin E3 ligase activity that targets IRF7 for proteosome-mediated degradation.
Ueda Y, Wang SE, Dumont N, Yi JY, Koh Y, Arteaga CL. J Biol Chem. 2004 Mar;279(23):24505-13. Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks TGF-ß-induced cell motility.
Wang SE, Wu FY, Chen H, Shamay M, Zheng Q, Hayward GS. J Virol. 2004 Apr;78(8):4248-67. Early activation of the Kaposi's sarcoma-associated herpesvirus RTA, RAP, and MTA promoters by the tetradecanoyl phorbol acetate-induced AP1 pathway.
Wu FY, Wang SE, Chen H, Wang L, Hayward SD, Hayward GS. J Virol. 2004 May;78(9):4847-65. CCAAT/enhancer binding protein alpha binds to the Epstein-Barr virus (EBV) ZTA protein through oligomeric interactions and contributes to cooperative transcriptional activation of the ZTA promoter through direct binding to the ZII and ZIIIB motifs during induction of the EBV lytic cycle.
Wang SE, Wu FY, Yu Y, Hayward GS. J Virol. 2003 Sep;77(17):9590-612. CCAAT/enhancer-binding protein-alpha is induced during the early stages of Kaposi's sarcoma-associated herpesvirus (KSHV) lytic cycle reactivation and together with the KSHV replication and transcription activator (RTA) cooperatively stimulates the viral RTA, MTA, and PAN promoters.
Wang SE, Wu FY, Fujimuro M, Zong J, Hayward SD, Hayward GS. J Virol. 2003 Jan;77(1): 600-23. Role of CCAAT/enhancer-binding protein alpha (C/EBPalpha) in activation of the Kaposi's sarcoma-associated herpesvirus (KSHV) lytic-cycle replication-associated protein (RAP) promoter in cooperation with the KSHV replication and transcription activator (RTA) and RAP.
This is a partial list. Full publications list available upon request. Information on this page may be self-reported and is subject to change at any time. Last updated: 02/09.
|
